Braintree
As of the edition of 20 October 2026, Braintree runs 17 drugs, 4 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 4 |
| Active | 1 |
| Went quiet | 10 |
| Stopped | 1 |
| Status not established | 1 |
| Total | 17 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Calcium | none listed | 0 |
| Calcium acetate | none listed | 0 |
| Nizatidine | none listed | 2 |
| Lactitol | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Digestive system: 5 trials led
- Skin and connective tissue: 3 trials led
- Cancer: 2 trials led